These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 11986789

  • 1. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa").
    Magné N, Fischel JL, Dubreuil A, Formento P, Poupon MF, Laurent-Puig P, Milano G.
    Br J Cancer; 2002 May 06; 86(9):1518-23. PubMed ID: 11986789
    [Abstract] [Full Text] [Related]

  • 2. The effect of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC-15 cells.
    Al-Hazzaa A, Bowen ID, Randerson P, Birchall MA.
    Cell Prolif; 2005 Apr 06; 38(2):77-86. PubMed ID: 15842252
    [Abstract] [Full Text] [Related]

  • 3. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
    Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, Clayman GL, Hong WK, Kumar R.
    Mol Cancer Ther; 2003 Apr 06; 2(4):345-51. PubMed ID: 12700278
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.
    Yang Z, Bagheri-Yarmand R, Wang RA, Adam L, Papadimitrakopoulou VV, Clayman GL, El-Naggar A, Lotan R, Barnes CJ, Hong WK, Kumar R.
    Clin Cancer Res; 2004 Jan 15; 10(2):658-67. PubMed ID: 14760089
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
    Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S.
    Ann Oncol; 2002 Jan 15; 13(1):65-72. PubMed ID: 11863114
    [Abstract] [Full Text] [Related]

  • 9. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
    Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PH.
    J Natl Cancer Inst; 2003 Dec 17; 95(24):1825-33. PubMed ID: 14679152
    [Abstract] [Full Text] [Related]

  • 10. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression.
    Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ.
    Int J Cancer; 2001 Dec 15; 94(6):774-82. PubMed ID: 11745477
    [Abstract] [Full Text] [Related]

  • 11. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.
    Albanell J, Rojo F, Baselga J.
    Semin Oncol; 2001 Oct 15; 28(5 Suppl 16):56-66. PubMed ID: 11706397
    [Abstract] [Full Text] [Related]

  • 12. Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer.
    Magné N, Fischel JL, Dubreuil A, Formento P, Marcié S, Lagrange JL, Milano G.
    Br J Cancer; 2002 Mar 04; 86(5):819-27. PubMed ID: 11875748
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil.
    Magné N, Fischel JL, Tiffon C, Formento P, Dubreuil A, Renée N, Formento JL, Francoual M, Ciccolini J, Etienne MC, Milano G.
    Br J Cancer; 2003 Aug 04; 89(3):585-92. PubMed ID: 12888834
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
    Campiglio M, Locatelli A, Olgiati C, Normanno N, Somenzi G, Viganò L, Fumagalli M, Ménard S, Gianni L.
    J Cell Physiol; 2004 Feb 04; 198(2):259-68. PubMed ID: 14603528
    [Abstract] [Full Text] [Related]

  • 18. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).
    Heimberger AB, Learn CA, Archer GE, McLendon RE, Chewning TA, Tuck FL, Pracyk JB, Friedman AH, Friedman HS, Bigner DD, Sampson JH.
    Clin Cancer Res; 2002 Nov 04; 8(11):3496-502. PubMed ID: 12429640
    [Abstract] [Full Text] [Related]

  • 19. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway.
    Sumitomo M, Asano T, Asakuma J, Asano T, Horiguchi A, Hayakawa M.
    Clin Cancer Res; 2004 Jan 15; 10(2):794-801. PubMed ID: 14760103
    [Abstract] [Full Text] [Related]

  • 20. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status.
    Suzuki T, Nakagawa T, Endo H, Mitsudomi T, Masuda A, Yatabe Y, Sugiura T, Takahashi T, Hida T.
    Lung Cancer; 2003 Oct 15; 42(1):35-41. PubMed ID: 14512185
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.